BIOSYENT INC. chart

Last update: 2021-02-19
Key statistics and financials
Revenue per share 2.24
Dividend & YieldN/AC$ (N/A)
Beta 0.92
Market capitalization 103.65M
Operating cash flow 5.48M
ESG Scores unknown

Company description

BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia. It also offers Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; and Proktis-M, a rectal suppository for the healing of the anus and rectum. In addition, it provides Combogesic for moderate acute pain and reduction of fever in adults; Protect-It, a non-chemical food-safe grain insecticide product used as a preventative treatment against insect infestations in stored grains; and Tibella, a hormone replacement therapy to treat vasomotor symptoms due to estrogen deficiency. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. was incorporated in 2006 and is headquartered in Mississauga, Canada.

Sector: Healthcare - Industry: Drug Manufacturers—Specialty & Generic

Financial data

Diluted earning per share

Net income vs Operating income

Asset vs Liabilities

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 163.47k 110.63k 1.78M -781.16k
Total Cashflows From Investing Activities -1.58M -1.32M 3.39M -4.84M
Net Borrowings -23.28k -23.28k -144.25k -151.95k
Total Cash From Financing Activities -505.27k -6.39M -3.37M -2.08M
Change To Operating Activities -153.5k -347.96k 341.18k -148.44k
Issuance Of Stock 100.92k 4.72k 7.42k 10.32k
Net Income 5.71M 4.37M 3.8M 6.28M
Change In Cash 4.18M -3.39M 6.85M -2.26M
Effect Of Exchange Rate -15.64k -90.57k -61.41k -18.55k
Total Cash From Operating Activities 6.29M 4.4M 6.89M 4.67M
Depreciation 152.32k 242.12k 471.57k 419.95k
Change To Account Receivables 53.94k 119.6k 214.13k -963.28k
Other Cashflows From Financing Activities -16.25k -16.25k -92.94k -85.25k
Change To Netincome 906.57k 680.96k 94.66k 111.36k
Capital Expenditures -34.97k -504.34k -13.62k -84.71k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development
Income Before Tax 7.55M 5.87M 5.24M 8.38M
Net Income 5.71M 4.37M 3.8M 6.28M
Selling General Administrative 9.71M 10.39M 12.39M 14.45M
Gross Profit 16.57M 16.65M 17.42M 22.64M
Ebit 6.86M 6.26M 5.03M 8.18M
Operating Income 6.86M 6.26M 5.03M 8.18M
Interest Expense -32.46k -32.46k -92.94k -85.25k
Income Tax Expense 1.84M 1.5M 1.44M 2.1M
Total Revenue 21.53M 21.42M 22.33M 28.62M
Cost Of Revenue 4.95M 4.78M 4.91M 5.98M
Total Other Income ExpenseNet 686.84k -388.56k 206.96k 195.22k
Net Income From Continuing Ops 5.71M 4.37M 3.8M 6.28M
Net Income Applicable To Common Shares 5.71M 4.37M 3.8M 6.28M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 3.58M 5.17M 6.78M 5.61M
Total Stockholder Equity 27.61M 25.79M 26.8M 31.55M
Other Current Liabilities 434.11k 297.95k 1.26M 412.32k
Total Assets 31.19M 30.97M 33.57M 37.17M
Common Stock 7.65M 7.18M 6.39M 5.8M
Other Current Assets 27.34k
Retained Earnings 18.99M 17.48M 19.08M 24.12M
Treasury Stock -14.73k -105.3k -166.71k -185.26k
Cash 16.83M 13.44M 20.29M 18.04M
Total Current Liabilities 3.21M 3.36M 5.14M 4.14M
Other Stockholder Equity -14.73k -105.3k -166.71k -185.26k
Property, Plant, and Equipment 178.29k 2.36M 2.07M 1.85M
Total Current Assets 28.35M 26.85M 29.77M 34.08M
Net Tangible Assets 25.64M 24.72M 25.83M 30.72M
Net Receivables 2.12M 2.08M 1.82M 3.21M
Accounts Payable 2.78M 2.92M 3.72M 3.56M


Insider Transactions

Here are the insider transactions of stock shares related to BIOSYENT INC.:

Filer Name Transaction Text Ownership Date Filer Relation Shares
Raghubir (Sharan)Grant of rights at price 7.27 per share.D2022-03-31Senior Officer of Issuer3.28k
Ashrafi (Seyed Ahmad)Grant of rights at price 7.27 per share.D2022-03-31Director of Issuer3.64k
Van Der Mark (Joost)D2022-03-31Senior Officer of Issuer5.72k
Arcuri, JosephD2022-03-31Senior Officer of Issuer1.07k
Atwal (Neelu)Grant of rights at price 7.27 per share.D2022-03-31Senior Officer of Issuer2.64k
Wilson, KevinGrant of rights at price 7.27 per share.D2022-03-31Senior Officer of Issuer3.64k
Moothan (Ramesh)Acquisition or disposition under a purchase/ownership plan at price 7.24 per share.D2022-03-31Director of Issuer1k
Moothan (Ramesh)Grant of rights at price 7.27 per share.D2022-03-31Director of Issuer2.86k
Goehrum (Rene Christopher)Grant of rights at price 7.27 per share.D2022-03-3110% Security Holder of Issuer15.18k
Lockhard (Peter Douglas)D2022-03-31Director of Issuer4.29k
March (Robert Joseph)Grant of rights at price 7.27 per share.D2022-03-31Senior Officer of Issuer5.9k
Moothan (Ramesh)Acquisition or disposition under a purchase/ownership plan at price 7.24 per share.D2022-03-29Director of Issuer1k
Wilson, KevinAcquisition or disposition under a purchase/ownership plan at price 7.22 per share.D2022-03-24Senior Officer of Issuer2.2k
Moothan (Ramesh)Acquisition or disposition under a purchase/ownership plan at price 7.26 per share.D2022-03-24Director of Issuer500
Raghubir (Sharan)Acquisition or disposition in the public market at price 6.09 per share.D2022-03-24Senior Officer of Issuer5.19k
Moothan (Ramesh)Acquisition or disposition under a purchase/ownership plan at price 7.12 per share.D2022-03-22Director of Issuer500
Raghubir (Sharan)Acquisition or disposition in the public market at price 6.99 per share.D2022-03-21Senior Officer of Issuer607
Raghubir (Sharan)Acquisition or disposition in the public market at price 6.61 per share.D2022-03-18Senior Officer of Issuer8.25k
Andrews (Larry)Acquisition or disposition under a purchase/ownership plan at price 6.04 per share.D2021-12-31Director of Issuer270
Goehrum (Rene Christopher)Acquisition or disposition under a purchase/ownership plan at price 6.10 per share.D2021-12-3110% Security Holder of Issuer1.52k
Arcuri, JosephAcquisition or disposition under a purchase/ownership plan at price 6.04 per share.D2021-12-31Senior Officer of Issuer88
Wilson, KevinAcquisition or disposition under a purchase/ownership plan at price 6.10 per share.D2021-12-31Senior Officer of Issuer737
Ashrafi (Seyed Ahmad)Acquisition or disposition under a purchase/ownership plan at price 6.10 per share.D2021-12-31Director of Issuer1.47k
Van Der Mark (Joost)D2021-12-31Senior Officer of Issuer858
March (Robert Joseph)Acquisition or disposition under a purchase/ownership plan at price 6.10 per share.D2021-12-31Senior Officer of Issuer2.24k
Atwal (Neelu)Acquisition or disposition under a purchase/ownership plan at price 6.10 per share.D2021-12-31Senior Officer of Issuer1.17k
Raghubir (Sharan)Acquisition or disposition under a purchase/ownership plan at price 6.10 per share.D2021-12-31Senior Officer of Issuer672
Moothan (Ramesh)Acquisition or disposition under a purchase/ownership plan at price 6.02 per share.D2021-12-13Director of Issuer560
Fax Capital CorpD2021-06-0910% Security Holder of Issuer
FAX Investments, Inc.I2021-06-0910% Security Holder of Issuer
Driscoll (Blair)I2021-06-0910% Security Holder of Issuer
Federated Capital CorpI2021-06-0910% Security Holder of Issuer
Driscoll, SeanI2021-06-0910% Security Holder of Issuer
Driscoll (Merrilyn Joy)I2021-06-0910% Security Holder of Issuer

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to BIOSYENT INC.. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on BIOSYENT INC.

Here is the result of two systematic investment strategies applied to BIOSYENT INC.. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on BIOSYENT INC.

The following chart shows the equity curve of the two systematic investment strategies applied to BIOSYENT INC.:

BIOSYENT INC. automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 10.7% on the backtest period.

Performance at glance

Performance

10.7 %

Latent gain

239.68 C$

Invested capital

2240.92 C$

Annualized return

2.54 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on BIOSYENT INC.

This is the result of two momentum investment strategies applied to BIOSYENT INC.. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on BIOSYENT INC.

The following chart shows all the entries opened by the momentum investment system on BIOSYENT INC.:

BIOSYENT INC. momentum entries
  • The first momentum investment strategy would give 10.13% of return on BIOSYENT INC.. That represents 428.92C$ of latent gain with 4233.98C$ of employed capital.
  • The second momentum investment strategy would give 13.44% of return on BIOSYENT INC.. That represents 336.59C$ of latent gain with 2505.11C$ of employed capital.
Performance at glance (1Q Momentum)

Performance

10.13 %

Latent gain

428.92 C$

Invested capital

4233.98 C$

Annualized return

2.55 %
Performance at glance (2Q Momentum)

Performance

13.44 %

Latent gain

336.59 C$

Invested capital

2505.11 C$

Annualized return

3.59 %

Momentum equity curve on BIOSYENT INC.

The following chart shows the equity curve of the two momentum strategies applied to BIOSYENT INC.:

BIOSYENT INC. momentum equity

Note: the dividends potentially given by BIOSYENT INC. are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on BIOSYENT INC.

The following chart shows the employed capital evolution of the two momentum strategies on BIOSYENT INC. since the beginning:

BIOSYENT INC.

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250C$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000C$.


Buy the dip strategy result on BIOSYENT INC.

Buy the dip entry openings on BIOSYENT INC.

BIOSYENT INC.

The performance achieved by the robo-advisor on BIOSYENT INC. is 5.66%. That represents 28.18$ of latent gain with 497.77C$ of employed capital. The following chart shows BIOSYENT INC. stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of BIOSYENT INC., and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

5.66 %

Latent gain

28.18 C$

Invested capital

497.77 C$

Annualized return

2.55 %

Equity curve of the strategy applied to BIOSYENT INC.

The following chart shows the result of the investment strategy applied to BIOSYENT INC.:

BIOSYENT INC.

Note: the dividends potentially given by BIOSYENT INC. are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on BIOSYENT INC.

The following chart shows the employed capital evolution since the beginning of the investment strategy on BIOSYENT INC.:

BIOSYENT INC.

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on BIOSYENT INC.

In this section, I will compare the three previous investment strategies applied to BIOSYENT INC..

Equity curve comparison on BIOSYENT INC.

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

BIOSYENT INC. investment strategy comparison

Employed capital comparison on BIOSYENT INC.

BIOSYENT INC. investment comparison

Performance comparison on BIOSYENT INC.

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 10.7% 239.68C$ 2240.92C$ 2.54%
Momentum 1 quarter 10.13% 428.92C$ 4233.98C$ 2.55%
Momentum 2 quarters 13.44% 336.59C$ 2505.11C$ 3.59%
Non-directional 5.66% 28.18C$ 497.77C$ 2.55%
Annualized return comparison

Automatic investment

2.54 %

Momentum 1Q

3.59 %

Momentum 2Q

3.59 %

Non-directional

2.55 %

Correlated stocks

Here are the most positively and negatively correlated stocks with BIOSYENT INC.:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between BIOSYENT INC. and the other stocks. There may be false positives or some missing correlated stocks. If the price of BIOSYENT INC. does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name BIOSYENT INC.
Country Canada
City Mississauga
Address 2476 Argentia Road
Phone
Website www.biosyent.com
FullTime employees
Industry Drug Manufacturers—Specialty & Generic
Sector Healthcare
Exchange XTSX
Ticker RX.XTSX
Market www.tsx.com

BIOSYENT INC. ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown